Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients

Elenir B C Avritscher, Ya Chen T Shih, Charlotte C. Sun, Richard J. Gralla, Steven M. Grunberg, Ying Xu, Linda S. Elting

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We estimated the cost-utility of palonosetron-based therapy compared with generic ondansetron-based therapy throughout four cycles of anthracycline and cyclophosphamide for treating women with breast cancer. We developed a Markov model comparing six strategies in which ondansetron and palonosetron are combined with either dexamethasone alone, dexamethasone plus aprepitant following emesis, or dexamethasone plus aprepitant up front. Data on the effectiveness of antiemetics and emesis-related utility were obtained from published sources. Relative to the ondansetron-based two-drug therapy, the incremental cost- effectiveness ratios for the palonosetron-based regimens were $115,490/quality-adjusted life years (QALY) for the twodrug strategy, $199,375/QALY for the two-drug regimen plus aprepitant after emesis, and $200,526/QALY for the three-drug strategy. In sensitivity analysis, using the $100,000/QALY benchmark, the palonosetronbased two-drug strategy and the two-drug regimen plus aprepitant following emesis were shown to be cost-effective in 39% and 26% of the Monte Carlo simulations, respectively, and with changes in values for the effectiveness of antiemetics and the rate of hospitalization. The cost-utility of palonosetron-based therapy exceeds the $100,000/QALY threshold. Future research incorporating the price structure of all antiemetics following ondansetron's recent patent expiration is needed.

Original languageEnglish (US)
Pages (from-to)242-251
Number of pages10
JournalJournal of Supportive Oncology
Volume8
Issue number6
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

aprepitant
Quality-Adjusted Life Years
Ondansetron
Cost-Benefit Analysis
Vomiting
Antiemetics
Breast Neoplasms
Dexamethasone
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics
Benchmarking
Anthracyclines
Cyclophosphamide
Hospitalization
palonosetron
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Avritscher, E. B. C., Shih, Y. C. T., Sun, C. C., Gralla, R. J., Grunberg, S. M., Xu, Y., & Elting, L. S. (2010). Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. Journal of Supportive Oncology, 8(6), 242-251. https://doi.org/10.1016/j.suponc.2010.09.027

Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. / Avritscher, Elenir B C; Shih, Ya Chen T; Sun, Charlotte C.; Gralla, Richard J.; Grunberg, Steven M.; Xu, Ying; Elting, Linda S.

In: Journal of Supportive Oncology, Vol. 8, No. 6, 11.2010, p. 242-251.

Research output: Contribution to journalArticle

Avritscher, EBC, Shih, YCT, Sun, CC, Gralla, RJ, Grunberg, SM, Xu, Y & Elting, LS 2010, 'Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients', Journal of Supportive Oncology, vol. 8, no. 6, pp. 242-251. https://doi.org/10.1016/j.suponc.2010.09.027
Avritscher, Elenir B C ; Shih, Ya Chen T ; Sun, Charlotte C. ; Gralla, Richard J. ; Grunberg, Steven M. ; Xu, Ying ; Elting, Linda S. / Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. In: Journal of Supportive Oncology. 2010 ; Vol. 8, No. 6. pp. 242-251.
@article{bdfefe23286a4177b37527d3f094bc6a,
title = "Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients",
abstract = "We estimated the cost-utility of palonosetron-based therapy compared with generic ondansetron-based therapy throughout four cycles of anthracycline and cyclophosphamide for treating women with breast cancer. We developed a Markov model comparing six strategies in which ondansetron and palonosetron are combined with either dexamethasone alone, dexamethasone plus aprepitant following emesis, or dexamethasone plus aprepitant up front. Data on the effectiveness of antiemetics and emesis-related utility were obtained from published sources. Relative to the ondansetron-based two-drug therapy, the incremental cost- effectiveness ratios for the palonosetron-based regimens were $115,490/quality-adjusted life years (QALY) for the twodrug strategy, $199,375/QALY for the two-drug regimen plus aprepitant after emesis, and $200,526/QALY for the three-drug strategy. In sensitivity analysis, using the $100,000/QALY benchmark, the palonosetronbased two-drug strategy and the two-drug regimen plus aprepitant following emesis were shown to be cost-effective in 39{\%} and 26{\%} of the Monte Carlo simulations, respectively, and with changes in values for the effectiveness of antiemetics and the rate of hospitalization. The cost-utility of palonosetron-based therapy exceeds the $100,000/QALY threshold. Future research incorporating the price structure of all antiemetics following ondansetron's recent patent expiration is needed.",
author = "Avritscher, {Elenir B C} and Shih, {Ya Chen T} and Sun, {Charlotte C.} and Gralla, {Richard J.} and Grunberg, {Steven M.} and Ying Xu and Elting, {Linda S.}",
year = "2010",
month = "11",
doi = "10.1016/j.suponc.2010.09.027",
language = "English (US)",
volume = "8",
pages = "242--251",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "6",

}

TY - JOUR

T1 - Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients

AU - Avritscher, Elenir B C

AU - Shih, Ya Chen T

AU - Sun, Charlotte C.

AU - Gralla, Richard J.

AU - Grunberg, Steven M.

AU - Xu, Ying

AU - Elting, Linda S.

PY - 2010/11

Y1 - 2010/11

N2 - We estimated the cost-utility of palonosetron-based therapy compared with generic ondansetron-based therapy throughout four cycles of anthracycline and cyclophosphamide for treating women with breast cancer. We developed a Markov model comparing six strategies in which ondansetron and palonosetron are combined with either dexamethasone alone, dexamethasone plus aprepitant following emesis, or dexamethasone plus aprepitant up front. Data on the effectiveness of antiemetics and emesis-related utility were obtained from published sources. Relative to the ondansetron-based two-drug therapy, the incremental cost- effectiveness ratios for the palonosetron-based regimens were $115,490/quality-adjusted life years (QALY) for the twodrug strategy, $199,375/QALY for the two-drug regimen plus aprepitant after emesis, and $200,526/QALY for the three-drug strategy. In sensitivity analysis, using the $100,000/QALY benchmark, the palonosetronbased two-drug strategy and the two-drug regimen plus aprepitant following emesis were shown to be cost-effective in 39% and 26% of the Monte Carlo simulations, respectively, and with changes in values for the effectiveness of antiemetics and the rate of hospitalization. The cost-utility of palonosetron-based therapy exceeds the $100,000/QALY threshold. Future research incorporating the price structure of all antiemetics following ondansetron's recent patent expiration is needed.

AB - We estimated the cost-utility of palonosetron-based therapy compared with generic ondansetron-based therapy throughout four cycles of anthracycline and cyclophosphamide for treating women with breast cancer. We developed a Markov model comparing six strategies in which ondansetron and palonosetron are combined with either dexamethasone alone, dexamethasone plus aprepitant following emesis, or dexamethasone plus aprepitant up front. Data on the effectiveness of antiemetics and emesis-related utility were obtained from published sources. Relative to the ondansetron-based two-drug therapy, the incremental cost- effectiveness ratios for the palonosetron-based regimens were $115,490/quality-adjusted life years (QALY) for the twodrug strategy, $199,375/QALY for the two-drug regimen plus aprepitant after emesis, and $200,526/QALY for the three-drug strategy. In sensitivity analysis, using the $100,000/QALY benchmark, the palonosetronbased two-drug strategy and the two-drug regimen plus aprepitant following emesis were shown to be cost-effective in 39% and 26% of the Monte Carlo simulations, respectively, and with changes in values for the effectiveness of antiemetics and the rate of hospitalization. The cost-utility of palonosetron-based therapy exceeds the $100,000/QALY threshold. Future research incorporating the price structure of all antiemetics following ondansetron's recent patent expiration is needed.

UR - http://www.scopus.com/inward/record.url?scp=78751470675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751470675&partnerID=8YFLogxK

U2 - 10.1016/j.suponc.2010.09.027

DO - 10.1016/j.suponc.2010.09.027

M3 - Article

C2 - 21265391

AN - SCOPUS:78751470675

VL - 8

SP - 242

EP - 251

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 6

ER -